BRIEF-Aviragen Therapeutics Issued Letter To Stockholders Urging Them To Vote For Proposed Deal With Vaxart [Reuters]
Atea Pharmaceuticals, Inc. - common stock (AVIR)
US:NASDAQ Investor Relations:
investors.aviragentherapeutics.com/news-releases/news-release-details/aviragen-therapeutics-and-vaxart-enter-merger-agreement
Company Research
Source: Reuters
BRIEF-Aviragen Therapeutics Issued Letter To Stockholders Urging Them To Vote For Proposed Deal With Vaxart | Reuters Reuters Staff 1 Min Read Jan 24 (Reuters) - Aviragen Therapeutics Inc: * AVIRAGEN THERAPEUTICS INC - ISSUED A LETTER TO STOCKHOLDERS URGING THEM TO VOTE FOR PROPOSED DEAL WITH VAXART AT SPECIAL MEETING OF STOCKHOLDERS Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2018 Reuters. All Rights Reserved. BRIEF-Aviragen Therapeutics Issued Letter To Stockholders Urging Them To Vote For Proposed Deal With Vaxart Jan 24 (Reuters) - Aviragen Therapeutics Inc: * AVIRAGEN THERAPEUTICS INC - ISSUED A LETTER TO STOCKHOLDERS URGING THEM TO VOTE FOR PROPOSED DEAL WITH VAXART AT SPECIAL MEETING OF STOCKHOLDERS Source text for Eikon: Further company coverage:
Show less
Read more
Impact Snapshot
Event Time:
AVIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVIR alerts
High impacting Atea Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
AVIR
News
- Global Dengue Pipeline Landscape Report 2024: Therapeutic Assessment and Drug Analysis of 20+ Drugs [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsGlobeNewswire
- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
AVIR
Earnings
- 2/28/24 - Miss
AVIR
Sec Filings
- 2/28/24 - Form 10-K
- 2/28/24 - Form 8-K
- 2/15/24 - Form SC
- AVIR's page on the SEC website